Daniel H Bedinger

Scientist
XOMA (US) LLC
Preclinical Research
Papers:
An Allosteric Monoclonal Antibody that Increases the Affinity of the Insulin Receptor for Insulin, and Preferentially Improves Insulin Signaling for the B but not the A Isoform of the Receptor
FP33-6 Inhibition of the Insulin Receptor Function by a Human, Allosteric, Monoclonal Antibody: a Novel Approach for the Treatment of Hyperinsulinemic Hypoglycemia